Record-Breaking Price Performance
On 6 May 2026, Asarfi Hospital Ltd’s stock closed at Rs 238.00, surpassing its previous 52-week high of Rs 236.40 by 0.68%. This new peak underscores the stock’s strong upward momentum, supported by a bullish technical trend that shifted on 5 May 2026 at Rs 234.05. Despite opening the day with a gap down of -2.16% and touching an intraday low of Rs 225.20 (-3.78%), the stock rebounded to close with a positive day change of 1.69%, outperforming the Sensex which was nearly flat at -0.02%.
Consistent Outperformance Against Benchmarks
Asarfi Hospital Ltd’s price appreciation over various time frames has been impressive when compared to broader market indices. Over the past one year, the stock has surged by 155.91%, vastly outpacing the Sensex’s decline of 4.51%. Year-to-date, the stock has gained 26.53%, while the Sensex has fallen by 9.64%. Even over shorter periods, the stock has demonstrated strength, with a one-month gain of 24.87% versus the Sensex’s 3.91%, and a one-week rise of 9.58% compared to the Sensex’s -0.63%. These figures highlight the stock’s market-beating performance within the hospital sector and micro-cap segment.
Technical Indicators and Moving Averages
The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the bullish trend. Technical indicators such as MACD and Bollinger Bands signal a predominantly bullish outlook on the weekly and monthly charts, while the Relative Strength Index (RSI) currently shows no extreme signals. Immediate support is identified at Rs 87.75, the 52-week low, with resistance levels at Rs 212.41 (20-day moving average area) and the major resistance at Rs 236.40, now surpassed.
Financial Strength and Quality Metrics
Asarfi Hospital Ltd’s financial results have been outstanding, contributing to the stock’s upward trajectory. The company reported its highest quarterly net sales at Rs 46.10 crores and a record quarterly PBDIT of Rs 10.11 crores. Net profit growth has been robust, with a 29.05% increase reported in the December 2025 quarter, marking the third consecutive quarter of positive results. The company’s return on capital employed (ROCE) reached a high of 18.55% in the half-year period, while the operating profit to net sales ratio stood at an impressive 21.93% for the quarter.
Valuation and Debt Metrics
Despite the strong price appreciation, Asarfi Hospital Ltd maintains an attractive valuation profile. The price-to-earnings (P/E) ratio stands at 28 times, with a price-to-book value (P/BV) of 4.91 times. The enterprise value to capital employed ratio is a modest 3.80 times, indicating efficient use of capital. The company’s debt position remains manageable, with a low debt to EBITDA ratio of 1.96 times and net debt to equity at 0.40, reflecting low leverage. This financial prudence supports the company’s ability to service debt effectively.
Long-Term Growth and Quality Assessment
Over the past five years, Asarfi Hospital Ltd has demonstrated healthy sales growth with a compound annual growth rate (CAGR) of 22.70%. However, operating profit growth has been more moderate at an annual rate of 14.76%. The company’s overall quality grade is assessed as average, with good capital structure and low promoter pledging. Institutional holdings remain low at 2.40%, and the company maintains a tax ratio of 27.70%. While growth metrics are solid, the average EBIT to interest coverage ratio of 3.30 times suggests moderate interest protection.
Shareholding and Market Capitalisation
The majority shareholding is held by promoters, providing stability in ownership. The company is classified as a micro-cap stock, which often entails higher volatility but also potential for significant price movements. Delivery volumes have shown a positive trend, with a 1-month delivery change of 10.09% and a notable 1-day delivery change of 92.09% compared to the 5-day average, indicating active trading interest.
Summary of Key Financial and Market Metrics
Asarfi Hospital Ltd’s recent performance is characterised by:
- All-time high stock price of Rs 238.00 on 6 May 2026
- One-year return of 155.91%, significantly outperforming the Sensex
- Strong quarterly financial results with record net sales and PBDIT
- Robust ROCE of 18.55% and manageable debt levels
- Trading above all major moving averages, confirming a bullish trend
These factors collectively illustrate the company’s solid market position and financial health, culminating in the recent milestone of reaching its highest-ever share price.
